2 leading ASX healthcare shares to buy and hold beyond 2030

Here we look at 2 leading ASX healthcare companies to buy and hold beyond 2030: CSL Limited (ASX: CSL) and ResMed Inc. (ASX: RMD).

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare sector has been one of the top-performing sectors on the ASX in recent years with strong share price gains from a number of healthcare companies.

In my opinion, healthcare will continue to be one of the top-performing ASX sectors over the next decade, along with the tech sector, as the demand for healthcare services and products continues to increase, both locally and internationally.

Here we examine 2 leading S&P/ASX 200 Index (ASX: XJO) healthcare shares: CSL Limited (ASX: CSL) and ResMed Inc (ASX: RMD). Both companies have evolved over the last 5 to 10 years to become leading international companies in their respective healthcare fields, with strong revenue and profit growth.

I believe that this strong growth will continue well into the next decade, which is likely to translate into continued strong share price growth.

Other specialist ASX healthcare shares which I believe have strong growth potential include Cochlear Limited (ASX: COH) and Nanosonics Ltd (ASX: NAN).

CSL Limited

CSL has developed into a highly successful global business through innovative research treatments that are protected by product patents, combined with the utilisation of a highly efficient global production and distribution network that generates strong cash returns. These returns are then cleverly reinvested back into the company to develop further innovative products and make targeted acquisitions.

In the 12 months to 30 June 2019, CSL invested over US$800 million into research and development across its businesses, which amounts to around 10% of its total operating revenue.

CSL produces blood medicines and plasma products that could potentially play a vital role in the production of products to help in the coronavirus fight. It does have a major division within its company that produces vaccines, which it has called upon in the past in previous health crises such as the swine flu.

ResMed Inc

ResMed is another amazing Aussie success story, growing from a backyard Australian operation 30 years ago to now become a major US-based global company employing more than 7,500 people worldwide.

The company is a leading designer and manufacturer of healthcare devices and cloud-based software solutions, targeting sleep apnea and other respiratory conditions. Its global scale and breadth now provide it with a distinct advantage over its competitors.

This specialist healthcare product provider is currently a leading provider of cloud-based software solutions for out of hospital care and is seeing particularly strong growth from its software-as-a-service (SaaS) segment, which now constitutes around 12% of its total revenue. This percentage is likely to grow significantly over the next 5 years.

I believe that the strong demand for ResMed's products is likely to persist over the next decade. It is estimated that over 20% of US adults are unaware that they are suffering from sleep apnea, providing ResMed with a large potential untapped revenue stream.

Phil Harpur owns shares of Cochlear Ltd., CSL Ltd., Nanosonics Limited, and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »